Back to Search
Dose-Finding Trial to Evaluate the Safety and Immunogenicity of Cytomegalovirus (CMV) Vaccine mRNA-1647 in Healthy Adults
Oklahoma City, Oklahoma, 73112
Hadar, Nebraska, 68701
Shawnee, Kansas, 66219
Lakeside, Texas, 76135
Victoria, Texas, 77901
Hadar, Nebraska, 68701
Shawnee, Kansas, 66219
Lakeside, Texas, 76135
Victoria, Texas, 77901
Search ended 05/30/2022
This clinical study will assess the safety and immunogenicity of 3 dose levels of mRNA-1647 cytomegalovirus vaccine in CMV-seronegative and CMV-seropositive healthy adults 18-40 years of age.
Eligibility
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, learn about Clinical
| Ages Eligible for Study | Min Age: 18 years - Max Age: 40 years |
| Sexes Eligible for Study | All |
| Accepts Healthy Volunteers | No |
Visit ClinicalTrials.Gov for more information
Support nonprofit organizations through participating in clinical trials at no cost to you
You may also be interested in
Palo Alto, California and more
A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors
Solid Tumor, Adult and more Read more
Grand Junction, CO and more
A Study of mRNA-1647 Cytomegalovirus Vaccine in Healthy Participants 9 to 15 Years of Age and Participants 16 to 25 Years of Age
Cytomegalovirus Read more
Rockville, Maryland and more